Chinese Journal of Tissue Engineering Research ›› 2012, Vol. 16 ›› Issue (36): 6724-6729.doi: 10.3969/j.issn.2095-4344.2012.36.013

Previous Articles     Next Articles

Intravenous transplantation of tissue inhibitor of metalloproteinase-1-transfected bone marrow mesenchymal stem cells for treatment of ischemic cardiomyopathy

Yi Hai-bo, Liu Jun, Jiang Li-hua   

  1. Department of Internal Medicine, Second Workers’ Hospital of Liaohe Oil Field, Panjin 124000, Liaoning
  • Received:2011-12-26 Revised:2012-02-19 Online:2012-09-02 Published:2012-09-02
  • About author:Yi Hai-bo, Attending physician, Department of Internal Medicine, Second Workers’ Hospital of Liaohe Oil Field, Panjin 124000, Liaoning Province, China yihaibopanjin@qq.com

Abstract:

BACKGROUND: Tissue inhibitor of metalloproteinase-1 (TIMP-1) can decrease the invasion of stem cells by inhibiting metalloproteinase activity and thereby increase the number of homing stem cells.
OBJECTIVE: To investigate whether intravenously injected bone marrow mesenchymal stem cells (BMSCs) can improve cardiac function in a rat myocardial infarction model.
METHODS: Myocardial infarction model was induced by occluding the anterior descending coronary artery in 56 SD rats. One week later, myocardial infarction models were assigned to four groups. Rats in the control, BMSCs, green fluorescent protein-BMSCs and TIMP-1- shRNA-BMSCs groups received DMEM, DMEM containing 1×107 BMSCs, DMEM containing 1×107 BMSCs transfected with green fluorescent protein gene lentiviral empty vector and DMEM containing 1×107 BMSCs transfected with TIMP-1-shRNA, respectively via the tail vein.
RESULTS AND CONCLUSION: After myocardial infarction induction, cardiac function was damaged and myocardial contractibility was decreased in each group. After treatment for 4 weeks, cardiac function improved to different extents. Compared with control group, rat myocardial contractibility was significantly increased (P < 0.05), myocardial infarction area was significantly reduced (P < 0.05), capillary density in the infarct area was significantly increased (P < 0.05) in the BMSCs, green fluorescent protein-BMSCs and TIMP-1- shRNA-BMSCs groups, and the improvement was better in the TIMP-1- shRNA-BMSCs group than in the BMSCs and green fluorescent protein-BMSCs groups (P < 0.05). These results suggest that transplantation of BMSCs transfected by TIMP-1 gene can greatly improve rat myocardial function and thereforecon be used for treatment of ischemic cardiomyopathy.

CLC Number: